Research programme: metabotropic glutamate receptor modulators - Sumitomo Pharma America
Latest Information Update: 22 Jul 2023
At a glance
- Originator Sunovion Pharmaceuticals
- Developer Sumitomo Pharma America
- Class
- Mechanism of Action Metabotropic glutamate receptor 5 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anxiety disorders; Autistic disorder; Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Anxiety-disorders in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autistic-disorder in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in USA